secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2026-08-06T20:10:06+00:00
Accession:  0001193125-26-338000
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tectonic Q2 net loss $22.3M; cash $227M; TX45 Phase 2 enrollment complete, IDMC recommends continuation
--------------------------------------------------------------------------------

- Net loss of $22.3M for Q2 2026 vs $20.0M in Q2 2025; R&D expenses $18.0M, G&A $6.2M.
- Cash and cash equivalents $227.1M as of June 30, 2026; cash runway into Q1 2029.
- TX45 APEX Phase 2 trial in PH-HFpEF completed enrollment (191 patients, 137 with CpcPH); IDMC recommended continuation; topline results expected early Q1 2027.
- TX2100 Phase 1a single dose cohorts completed; topline results expected by end of Q3 2026; Phase 2 planned early 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000119312526338000/0001193125-26-338000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000119312526338000/d114671d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-338000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer